Matthew B. Klein Sells 2,244 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) COO Matthew B. Klein sold 2,244 shares of PTC Therapeutics stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $44.36, for a total transaction of $99,543.84. Following the transaction, the chief operating officer now directly owns 77,856 shares of the company’s stock, valued at $3,453,692.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

PTC Therapeutics Stock Down 0.1 %

PTCT opened at $47.78 on Friday. The firm has a 50 day moving average price of $39.30 and a 200-day moving average price of $44.91. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of -6.40 and a beta of 0.50. PTC Therapeutics, Inc. has a twelve month low of $25.01 and a twelve month high of $55.58.

PTC Therapeutics (NASDAQ:PTCT – Get Rating) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by ($0.16). The company had revenue of $217.13 million for the quarter, compared to the consensus estimate of $194.18 million. As a group, analysts expect that PTC Therapeutics, Inc. will post -6.79 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on PTCT shares. Royal Bank of Canada lowered their price target on shares of PTC Therapeutics from $60.00 to $46.00 and set a “sector perform” rating for the company in a research report on Friday, October 28th. Cowen decreased their target price on shares of PTC Therapeutics to $44.00 in a report on Tuesday, November 1st. Barclays decreased their target price on shares of PTC Therapeutics to $47.00 in a report on Tuesday, November 1st. Morgan Stanley decreased their target price on shares of PTC Therapeutics from $54.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday, October 28th. Finally, The Goldman Sachs Group started coverage on shares of PTC Therapeutics in a report on Wednesday, December 14th. They issued a “sell” rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.73.

Institutional Trading of PTC Therapeutics

Large investors have recently added to or reduced their stakes in the business. Motley Fool Asset Management LLC grew its position in PTC Therapeutics by 16.3% during the second quarter. Motley Fool Asset Management LLC now owns 38,277 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 5,351 shares during the period. CM Management LLC boosted its position in shares of PTC Therapeutics by 12.5% in the second quarter. CM Management LLC now owns 45,000 shares of the biopharmaceutical company’s stock worth $1,803,000 after purchasing an additional 5,000 shares during the period. Walleye Capital LLC boosted its position in shares of PTC Therapeutics by 502.1% in the second quarter. Walleye Capital LLC now owns 60,412 shares of the biopharmaceutical company’s stock worth $2,420,000 after purchasing an additional 50,379 shares during the period. Integral Health Asset Management LLC boosted its position in shares of PTC Therapeutics by 149.2% in the second quarter. Integral Health Asset Management LLC now owns 104,656 shares of the biopharmaceutical company’s stock worth $4,193,000 after purchasing an additional 62,656 shares during the period. Finally, Nadler Financial Group Inc. bought a new position in shares of PTC Therapeutics in the third quarter worth approximately $248,000.

PTC Therapeutics Company Profile

(Get Rating)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.